Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan 1;46(1):65-74.
doi: 10.2337/dc22-0383.

Deficits and Disparities in Early Uptake of Glucagon-Like Peptide 1 Receptor Agonists and SGLT2i Among Medicare-Insured Adults Following a New Diagnosis of Cardiovascular Disease or Heart Failure

Sara J Cromer  1   2   3 , Julie C Lauffenburger  1   3 , Raisa Levin  1 , Elisabetta Patorno  1   3
Affiliations

Deficits and Disparities in Early Uptake of Glucagon-Like Peptide 1 Receptor Agonists and SGLT2i Among Medicare-Insured Adults Following a New Diagnosis of Cardiovascular Disease or Heart Failure

Sara J Cromer et al. Diabetes Care. .

Abstract

Objective: To examine the association of race/ethnicity and socioeconomic deprivation with initiation of guideline-recommended diabetes medications with cardiovascular benefit (glucagon-like peptide 1 receptor agonists [GLP1-RA] and sodium-glucose cotransporter 2 inhibitors [SGLT2i]) among older adults with type 2 diabetes (T2D) and either incident atherosclerotic cardiovascular disease (ASCVD) or congestive heart failure (CHF).

Research design and methods: Using Medicare data (2016-2019), we identified 4,057,725 individuals age >65 years with T2D and either incident ASCVD or CHF. We estimated incidence rates and hazard ratios (HR) of GLP1-RA or SGLT2i initiation within 180 days by race/ethnicity and zip code-level Social Deprivation Index (SDI) using adjusted Cox proportional hazards models.

Results: Incidence rates of GLP1-RA or SGLT2i initiation increased over time but remained low (<0.6 initiations per 100 person-months) in all years studied. Medication initiation was less common among those of Black or other race/ethnicity (HR 0.81 [95% CI 0.79-0.84] and HR 0.84 [95% CI 0.75-0.95], respectively) and decreased with increasing SDI (HR 0.96 [95% CI 0.96-0.97]). Initiation was higher in ASCVD than CHF (0.35 vs. 0.135 initiations per 100 person-months). Moderate (e.g., nephropathy, nonalcoholic fatty liver disease) but not severe (e.g., advanced chronic kidney disease, cirrhosis) comorbidities were associated with higher probability of medication initiation.

Conclusions: Among older adults with T2D and either ASCVD or CHF, initiation of GLP1-RA or SGLT2i was low, suggesting a substantial deficit in delivery of guideline-recommended care or treatment barriers. Individuals of Black and other race/ethnicity and those with higher area-level socioeconomic deprivation were less likely to initiate these medications.

PubMed Disclaimer

Conflict of interest statement

Duality of Interest. S.J.C. reports employment of a close family member by a Johnson & Johnson company. E.P. is co-investigator of a research grant to the Brigham and Women’s Hospital from Boehringer Ingelheim, outside the submitted work. No other potential conflicts of interest relevant to this article were reported.

Figures

Figure 1
Figure 1
Flow diagram. CED, cohort entry date; CKD5, chronic kidney disease stage 5; ESRD, end-stage renal disease.
See this image and copyright information in PMC

References

    1. Marso SP, Bain SC, Consoli A, et al. .; SUSTAIN-6 Investigators . Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834–1844 - PubMed
    1. Marso SP, Daniels GH, Brown-Frandsen K, et al. .; LEADER Steering Committee; LEADER Trial Investigators . Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311–322 - PMC - PubMed
    1. Husain M, Birkenfeld AL, Donsmark M, et al. . Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019. 29;381:841–851 - PubMed
    1. Gerstein HC, Colhoun HM, Dagenais GR, et al. .; REWIND Investigators . Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019;394:121–130 - PubMed
    1. Holman RR, Bethel MA, Mentz RJ, et al. .; EXSCEL Study Group . Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017;377:1228–1239 - PMC - PubMed

Publication types

Substances